# Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

> **NCT00954941** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 100 (actual)

## Conditions studied

- Hematologic Diseases
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
- Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** Ondansetron
- **DRUG:** Aprepitant

## Key facts

- **NCT ID:** NCT00954941
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2013-04
- **Final completion:** 2015-05
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2015-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00954941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00954941, "Ondansetron Versus Aprepitant Plus Ondansetron for Emesis". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00954941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*